Journal of Gastrointestinal Infections

Register      Login

VOLUME 10 , ISSUE 1 ( January-December, 2020 ) > List of Articles


Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians

Arshdeep Singh, Vandana Midha, Harmeet Kaur, Ajit Sood

Citation Information : Singh A, Midha V, Kaur H, Sood A. Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians. J Gastrointest Infect 2020; 10 (1):16-25.

DOI: 10.5005/jp-journals-10068-3041

License: CC BY-NC 4.0

Published Online: 01-06-2021

Copyright Statement:  Copyright © 2020; The Author(s).


Gut microbiota has emerged as an important player in the pathogenesis of various intestinal and extraintestinal diseases. Microbiota-targeted therapies, such as probiotics, prebiotics, antibiotics, dietary interventions, and fecal microbiota transplantation (FMT), are therefore being considered and tested as therapies for such diseases. In this review, we discuss the mechanisms and clinical applications of FMT with focus on Clostridioides difficile infection, inflammatory bowel disease, and irritable bowel syndrome. We also discuss practical issues concerning the clinical use of FMT.

  1. Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946–953. DOI: 10.1053/j.gastro.2013.08.058.
  2. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012;107(11):1755. DOI: 10.1038/ajg.2012.251.
  3. DePeters EJ, George LW. Rumen transfaunation. Immunol Lett 2014;162(2 Pt A):69–76. DOI: 10.1016/j.imlet.2014.05.009.
  4. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44(5):854–859.
  5. Halkjær SI, Boolsen AW, Günther S, et al. Can fecal microbiota transplantation cure irritable bowel syndrome? World J Gastroenterol 2017;23(22):4112–4120. DOI: 10.3748/wjg.v23.i22.4112.
  6. Imdad A, Nicholson MR, Tanner-Smith EE, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2018;11(11):CD012774. DOI: 10.1002/14651858.CD012774.pub2.
  7. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143(4):913–916.e7. DOI: 10.1053/j.gastro.2012.06.031.
  8. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017;66(6):1727–1738. DOI: 10.1002/hep.29306.
  9. Leshem A, Horesh N, Elinav E. Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome. Front Immunol 2019;10:1341. DOI: 10.3389/fimmu.2019.01341.
  10. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017;474(11):1823–1836. DOI: 10.1042/BCJ20160510.
  11. Zou Y, Xue W, Luo G, et al. 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses. Nat Biotechnol 2019;37(2):179–185. DOI: 10.1038/s41587-018-0008-8.
  12. Filyk HA, Osborne LC. The multibiome: the intestinal ecosystem's influence on immune homeostasis, health, and disease. EBioMedicine 2016;13:46–54. DOI: 10.1016/j.ebiom.2016.10.007.
  13. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011;473(7346):174–180. DOI: 10.1038/nature09944.
  14. Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 2019;7(1):14. DOI: 10.3390/microorganisms7010014.
  15. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013;138(1):1–11. DOI: 10.1111/j.1365-2567.2012.03616.x.
  16. Thakur A, Mikkelsen H, Jungersen G. Intracellular pathogens: host immunity and microbial persistence strategies. J Immunol Res 2019;2019:1356540. DOI: 10.1155/2019/1356540.
  17. Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 2013;51(9):2884–2892. DOI: 10.1128/JCM.00845-13.
  18. Weingarden A, González A, Vázquez-Baeza Y, et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome 2015;3:10. DOI: 10.1186/s40168-015-0070-0.
  19. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146(6):1489–1499. DOI: 10.1053/j.gastro.2014.02.009.
  20. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149(1):102–109.e6. DOI: 10.1053/j.gastro.2015.04.001.
  21. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive Fecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017;389(10075): 1218–1228. DOI: 10.1016/S0140-6736(17)30182-4.
  22. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149(1):110–118.e4. DOI: 10.1053/j.gastro.2015.03.045.
  23. Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 2019;321(2):156–164. DOI: 10.1001/jama.2018.20046.
  24. Wang L, Alammar N, Singh R, et al. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J Acad Nutr Diet 2020;120(4):565–586. DOI: 10.1016/j.jand.2019.05.015.
  25. Ng KM, Ferreyra JA, Higginbottom SK, et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013;502(7469):96–99. DOI: 10.1038/nature12503.
  26. Chen HC, Chang CC, Mau WJ, et al. Evaluation of N- acetylchitooligosaccharides as the main carbon sources for the growth of intestinal bacteria. FEMS Microbiol Lett 2002;209(1):53–56. DOI: 10.1111/j.1574-6968.2002.tb11108.x.
  27. Ellermann M, Arthur JC. Siderophore-mediated iron acquisition and modulation of host-bacterial interactions. Free Radic Biol Med 2017;105:68–78. DOI: 10.1016/j.freeradbiomed.2016.10.489.
  28. Kopke M, Straub M, Durre P. Clostridium difficile is an autotrophic bacterial pathogen. PLoS One. 2013;8(4):e62157. DOI: 10.1371/journal.pone.0062157.
  29. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008;65(16): 2461–2483. DOI: 10.1007/s00018-008-7568-6.
  30. Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014;306(4):G310–G319. DOI:10.1152/ajpgi.00282.2013.
  31. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 2010;10(3):159–169. DOI: 10.1038/nri2710.
  32. Francino MP. Early development of the gut microbiota and immune health. Pathogens 2014;3(3):769–790. DOI: 10.3390/pathogens3030769.
  33. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453(7195): 620–625. DOI: 10.1038/nature07008.
  34. Glover LE, Lee JS, Colgan SP. Oxygen metabolism and barrier regulation in the intestinal mucosa. J Clin Invest 2016;126(10): 3680–3688. DOI: 10.1172/JCI84429.
  35. Burrello C, Garavaglia F, Cribiù FM, et al. Therapeutic Fecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nat Commun 2018;9(1):5184. DOI: 10.1038/s41467-018-07359-8.
  36. Ekmekciu I, Von Klitzing E, Fiebiger U, et al. Immune responses to broad-spectrum antibiotic treatment and fecal microbiota transplantation in mice. Front Immunol 2017;8:397. DOI: 10.3389/fimmu.2017.00397.
  37. Ekmekciu I, Von Klitzing E, Neumann C, et al. Fecal microbiota transplantation, commensal Escherichia coli and Lactobacillus johnsonii strains differentially restore intestinal and systemic adaptive immune cell populations following broad-spectrum antibiotic treatment. Front Microbiol 2017;8:2430. DOI: 10.3389/fmicb.2017.02430.
  38. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5): 407–415. DOI: 10.1056/NEJMoa1205037.
  39. Cammarota G, Masucci L, Ianiro G, et al. Randomized clinical trial: fecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015;41(9):835–843. DOI: 10.1111/apt.13144.
  40. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection: a randomized trial. Ann Intern Med 2016;165(9): 609–616. DOI: 10.7326/M16-0271.
  41. Vaishnavi C. Fecal microbiota transplantation for management of Clostridium difficile infection. Indian J Gastroenterol 2014;33(4): 301–307. DOI: 10.1007/s12664-014-0459-x.
  42. Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017;46(5):479–493. DOI: 10.1111/apt.14201.
  43. Hui W, Li T, Liu W, et al. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLoS One 2019;14(1):e0210016. DOI: 10.1371/journal.pone.0210016.
  44. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent clostridium difficile infection. Gastroenterology 2019;156(5): 1324–1332. DOI: 10.1053/j.gastro.2018.12.019.
  45. Fischer M, Sipe BW, Rogers NA, et al. Fecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 2015;42(4):470–476. DOI: 10.1111/apt.13290.
  46. Fischer M, Sipe B, Cheng YW, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes 2017;8(3):289–302. DOI: 10.1080/19490976.2016.1273998.
  47. Ianiro G, Masucci L, Quaranta G, et al. Randomized clinical trial: Fecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther 2018;48(2):152–159. DOI: 10.1111/apt.14816.
  48. Hocquart M, Lagier JC, Cassir N, et al. Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections. Clin Infect Dis 2018;66(5):645–650. DOI: 10.1093/cid/cix762.
  49. Juul FE, Garborg K, Bretthauer M, et al. Fecal microbiota transplantation for primary clostridium difficile infection. N Engl J Med 2018;378(26):2535–2536. DOI: 10.1056/NEJMc1803103.
  50. Camacho-Ortiz A, Gutiérrez-Delgado EM, Garcia-Mazcorro JF, et al. Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome. PLoS One 2017;12(12):e0189768. DOI: 10.1371/journal.pone.0189768.
  51. Cammarota G, Ianiro G, Tilg H, et al. European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66(4):569–580. DOI: 10.1136/gutjnl-2016-313017.
  52. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989;1(8630):164. DOI: 10.1016/s0140-6736(89)91183-5.
  53. Borody TJ, George L, Andrews P, et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989;150(10):604.
  54. Butta H, Kapoor A, Sibal A, et al. Fecal microbial transplant: a new hope of treatment for ulcerative colitis. Int J Med Public Health 2018;8(1):7–10. DOI: 10.5530/ijmedph.2018.1.2.
  55. Seth AK, Rawal P, Bagga R, et al. Successful colonoscopic fecal microbiota transplantation for active ulcerative colitis: first report from India. Indian J Gastroenterol 2016;35(5):393–395. DOI: 10.1007/s12664-016-0696-2.
  56. Goyal A, Yeh A, Bush BR, et al. Safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease. Inflamm Bowel Dis 2018;24(2): 410–421. DOI: 10.1093/ibd/izx035.
  57. Sood A, Mahajan R, Juyal G, et al. Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis. Intest Res 2019;17(1):78–86. DOI: 10.5217/ir.2018.00089.
  58. Moayyedi P. Update on fecal microbiota transplantation in patients with inflammatory bowel disease. Gastroenterol Hepatol 2018;14(5):319–322.
  59. Sood A, Mahajan R, Singh A, et al. Role of fecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis 2019;13(10):1311–1317. DOI: 10.1093/ecco-jcc/jjz060.
  60. Li Q, Zhang T, Ding X, et al. Enhancing patient adherence to fecal microbiota transplantation maintains the long-term clinical effects in ulcerative colitis. European J Gastroenterol Hepatol 2020;32(8): 955–962. DOI: 10.1097/MEG.0000000000001725.
  61. Sokol H, Landman C, Seksik P, et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome 2020;8(1):12. DOI: 10.1186/s40168-020-0792-5.
  62. Yang Z, Bu C, Yuan W, et al. Fecal microbiota transplant via endoscopic delivering through small intestine and colon: no difference for Crohn's disease. Dig Dis Sci 2020;65(1):150–157. DOI: 10.1007/s10620-019-05751-y.
  63. Vaughn BP, Vatanen T, Allegretti JR, et al. Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn's disease. Inflamm Bowel Dis 2016;22(9):2182–2190. DOI: 10.1097/MIB.0000000000000893.
  64. Wang H, Cui B, Li Q, et al. The safety of fecal microbiota transplantation for Crohn's disease: findings from a long-term study. Adv Ther 2018;35(11):1935–1944. DOI: 10.1007/s12325-018-0800-3.
  65. Carroll IM, Ringel-Kulka T, Siddle JP, et al. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24(6):521–530, e248.DOI: 10.1111/j.1365-2982.2012.01891.x.
  66. Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017;152(1):111–123.e8. DOI: 10.1053/j.gastro.2016.09.049.
  67. Shukla R, Ghoshal U, Dhole TN, et al. Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis. Dig Dis Sci 2015;60(10):2953–2962. DOI: 10.1007/s10620-015-3607-y.
  68. Halkjær SI, Christensen AH, Lo BZ, et al. Fecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomized, double-blind placebo-controlled study. Gut 2018;67(12):2107–2115. DOI: 10.1136/gutjnl-2018-316434.
  69. Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Fecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomized, placebo-controlled, parallel-group, single-center trial. Lancet Gastroenterol Hepatol 2018;3(1):17–24. DOI: 10.1016/S2468-1253(17)30338-2.
  70. Holvoet T, Joossens M, Jerina B, et al. Fecal microbiota transplantation in irritable bowel syndrome with predominant abdominal bloating: results from a double blind, placebo-controlled clinical trial. Gastroenterology 2018;154(6):S-130. DOI: 10.1016/S0016-5085(18)30860-6.
  71. El-Salhy M, Hatlebakk JG, Gilja OH, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomized, double-blind, placebo-controlled study. Gut. 2020;69(5):859–867. DOI: 10.1136/gutjnl-2019-319630.
  72. Lahtinen P, Jalanka J, Hartikainen A, et al. Randomized clinical trial: Fecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther 2020;51(12):1321–1331. DOI: 10.1111/apt.15740.
  73. Ianiro G, Eusebi LH, Black CJ, et al. Systematic review with meta-analysis: efficacy of Fecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2019;50(3):240–248. DOI: 10.1111/apt.15330.
  74. Xu D, Chen VL, Steiner CA, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2019;114(7):1043–1050. DOI: 10.14309/ajg.0000000000000198.
  75. Sood A, Ahuja V, Kedia S, et al. Diet and inflammatory bowel disease: The Asian Working Group guidelines [published correction appears in Indian J Gastroenterol 2019;38(6):558–559]. Indian J Gastroenterol 2019;38(3):220–246. DOI: 10.1007/s12664-019-00976-1.
  76. Wilson BC, Vatanen T, Cutfield WS, et al. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol 2019;9:2. DOI: 10.3389/fcimb.2019.00002.
  77. Zhang F, Zhang T, Zhu H, et al. Evolution of fecal microbiota transplantation in methodology and ethical issues. Curr Opin Pharmacol 2019;49:11–16. DOI: 10.1016/j.coph.2019.04.004.
  78. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016;315(2):142–149. DOI: 10.1001/jama.2015. 18098.
  79. Papanicolas LE, Choo JM, Wang Y, et al. Bacterial viability in fecal transplants: which bacteria survive? EBioMedicine 2019;41:509–516. DOI: 10.1016/j.ebiom.2019.02.023.
  80. Jiang ZD, Alexander A, Ke S, et al. Stability and efficacy of frozen and lyophilized Fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI). Anaerobe 2017;48:110–114. DOI: 10.1016/j.anaerobe.2017.08.003.
  81. Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomized clinical trial: faecal microbiota transplantation for recurrent Clostridium difficile infection – fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther 2017;45(7):899–908. DOI: 10.1111/apt.13969.
  82. Costello SP, Tucker EC, La Brooy J, et al. Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 2016;62(7):908–914. DOI: 10.1093/cid/civ994.
  83. Keshteli AH, Millan B, Madsen KL. Pretreatment with antibiotics may enhance the efficacy of Fecal microbiota transplantation in ulcerative colitis: a meta-analysis. Mucosal Immunol 2017;10(2):565–566. DOI: 10.1038/mi.2016.123.
  84. Freitag TL, Hartikainen A, Jouhten H, et al. Minor effect of antibiotic pre-treatment on the engraftment of donor microbiota in fecal transplantation in mice. Front Microbiol 2019;10:2685. DOI: 10.3389/fmicb.2019.02685.
  85. Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open 2016;4(6):E610–E613. DOI: 10.1055/s-0042-105205.
  86. Gweon TG, Kim J, Lim CH, et al. Fecal microbiota transplantation using upper gastrointestinal tract for the treatment of refractory or severe complicated clostridium difficile infection in elderly patients in poor medical condition: the first study in an Asian country. Gastroenterol Res Pract 2016;2016:2687605. DOI: 10.1155/2016/2687605.
  87. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One 2016;11(8):e0161174. DOI: 10.1371/journal.pone.0161174.
  88. Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2017;318(20): 1985–1993. DOI: 10.1001/jama.2017.17077.
  89. Steube A, Vital M, Grunert P, et al. Long-term multidonor fecal microbiota transfer by oral capsules for active ulcerative colitis. J Crohns Colitis 2019;13(11):1480–1481. DOI: 10.1093/ecco-jcc/jjz073.
  90. Mizuno S, Nanki K, Matsuoka K, et al. Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients. Intest Res 2017;15(1):68–74. DOI: 10.5217/ir.2017.15.1.68.
  91. Staley C, Kaiser T, Vaughn BP, et al. Durable long-term bacterial engraftment following encapsulated fecal microbiota transplantation to treat Clostridium difficile infection. mBio 2019;10(4). DOI: 10.1128/mBio.01586-19.
  92. Tabbaa OM, Aboelsoud MM, Mattar MC. Long-term safety and efficacy of fecal microbiota transplantation in the treatment of Clostridium difficile infection in patients with and without inflammatory bowel disease: a tertiary care centre's experience. Gastroenterology Res 2018;11(6):397–403. DOI: 10.14740/gr1091.
  93. Lee CH, Chai J, Hammond K, et al. Long-term durability and safety of Fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure. Eur J Clin Microbiol Infect Dis 2019;38(9):1731–1735. DOI: 10.1007/s10096-019-03602-2.
  94. Jalanka J, Hillamaa A, Satokari R, et al. The long-term effects of fecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2018;47(3):371–379. DOI: 10.1111/apt.14443.
  95. Sood A, Singh A, Mahajan R, et al. Acceptability, tolerability, and safety of fecal microbiota transplantation in patients with active ulcerative colitis (AT&S Study). J Gastroenterol Hepatol 2020;35(3):418–424. DOI: 10.1111/jgh.14829.
  96. DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-Resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019;381(21):2043–2050. DOI: 10.1056/NEJMoa1910437.
  97. Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010;71(3):446–454. DOI: 10.1016/j.gie.2009.10.027.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.